zeus (@zeusPharma) header
zeus (@zeusPharma) profile picture

BioGen

United States
Joined November 2013
Photo by zeus (@zeusPharma)Photo by zeus (@zeusPharma)Photo by zeus (@zeusPharma)Photo by zeus (@zeusPharma)Photo by zeus (@zeusPharma)Photo by zeus (@zeusPharma)Photo by zeus (@zeusPharma)Photo by zeus (@zeusPharma)Photo by zeus (@zeusPharma)Photo by zeus (@zeusPharma)
Wish everyone a happy holiday and prosperous 2025. My speculative bets on small biotech for 2025 are $SGMO and $INMB. My long-term holds are $NTLA and $MRNA. My sure bet is on TIPS (Treasury Inflation-Protected Securities).
1
3
14
2,641
Shuts down Ebola research - Massive Ebola outbreak Closes CDC Parasitology division - Huge parasitic diarrhoea outbreak Defunds screwworm research - screwworm comes back to the US Bashes vaccines - measles roars back Ladies and gentlemen I give you Health Secretary RFK Jr
671
5,160
279
13,750
165,833
$SGMO owns valuable technologies. Will it survive the current money crunch and realize its potential? It’s has been painful to own the stock.
7
1,456
Incredibly relevant to the times we live in
258
5,425
198
13,368
749,891
During a gathering with friends past weekend, one asked the question of what was it like before the Big Bang? I answered him that there was no “before” the Big Bang. Time and space only started with the Big Bang!
106
Efficacy, ease of administration, and once-and-done will make $NTLA products the standards of care for HAE and ATTR. Annual sales will be more $10B by 2034. What should be the current valuation?
1
11
927
Overexpress proteins in CNS will always be challenging. Immune response in CNS is difficult to manage. Suppression of proteins should not have similar issues (Tau, SYN, PRP). Capsida, $VYGR, $SGMO. Look forward to clinical testing on PRP suppression.
1
8
700
$SGMO Early treatment with ST-920 is key to restore kidney function. Patients with mild kidney damage (eGFR>60) show the most improvement. This is further supported by results from female patients. Miracle drug for Fabry patients!
3
27
1,395
$SGMO Fabry deal will be done within 4 weeks. The upfront money will be less than expected (SGMO demands for 2 years of funding of ~250 to 300M). Now upfront will be ~150M with approval of additional $80M. ~15% royalty.
9
1
25
3,247
$INMB Can anyone analyze the psychology for Monday morning? If totally negative, Friday after hours would be perfect. If blown away positive, why wait for 3 days?
1
1
620
$SGMO “Furthermore, a mean annualized eGFR slope of 1.747 mL/min/1.73m2/year (95% CI: -0.106, 3.601) was observed for the 19 patients who have achieved 104-weeks of follow-up” Patients gained years of kidney function after two years on treatment.
2
2
18
1,621
$SGMO As the median age of patients is in their 40s, most of them will gain back about ~5 years of kidney function in terms of eGFR after two years. The general population loses about 6 to 7 points between the age 40 and 50. It’s a miracle drug for Fabry patients.
1
18
1,068
With mature data, approval is near certainty both in US and EU. $SGMO needs to get an experienced partner. It will reach peak sales of over 1B for over a decade.
1
2
28
3,510
$SRPT, $SGMO FDA should set up a dose limit for AAV vectors. it should be somewhere around 5x10^13/kg, in my opinion. Furthermore, there should be a limit for the usage of immune suppressors. ELEVIDYS requires strong immune suppression, whereas ST-920 does not use any.
3
3
1
25
4,790
$NTLA, $PRME, $CRSP, $SGMO Genomic medicine will be going main stream and some big pharmas will miss the boat. LNP will be the main delivery tool for pure gene editing (change genome) ex-CNS. It’s economical and redosable.
4
13
1,656
AAVs have advantages for overexpression in cases of lysosomal storage disease as super physiological concentrations may be required. For CNS delivery, emerging AAVs from $SGMO, $VYGR, Capsida will be critical for success. Non-genome-editing gene therapy could be advantageous.
1
1
5
1,041
$SGMO ZINC FINGER SUPPRESSORS (ZFRs) or ACTIVATORS (ZFAs) have advantages. Tough investing and regulatory environments will bankrupt some of them. A good CEO will be the key. Survivors will be big.
6
621
In the upcoming deal for ST-920, it is likely to include equity investment due to the current dismal share price of $SGMO. Possible 9.9% equity investment for $120M in addition to up front payment of $100 to 200M.
1
1
14
1,249
$SGMO Transformative treatments such as ST-920 and NTLA-2002 will be approved regardless of who’s in charge of the FDA. The only downside for ST-920 seems to be that it can only be used for about half of the patients due to seropositivity for AAV6.
1
15
1,326